Anthrax Immune Globulin
Anthrax Immune Globulin (AIG) is a specialized biological product made from human plasma containing antibodies against Bacillus anthracis. It is used as adjunctive treatment for inhalational anthrax, working alongside antibiotic therapy to neutralize anthrax toxins in the bloodstream. This medication is particularly important in severe cases where toxin-mediated damage poses significant risk to patient outcomes.
Anthrax Immune Globulin is an antibody treatment used alongside antibiotics to treat inhalational anthrax by neutralizing bacterial toxins.
Key facts at a glance
- ATC
- J06BB19
- RxNorm
- 1722336
- Generic
- Anthrax Immune Globulin
- Class
- atc-j06
- Brands
- Anthrasil
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 420 IU/kg (anti-protective antigen IgG)
- Maximum
- consult physician
- Frequency
- single infusion over 2 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 420 IU/kg (anti-protective antigen IgG)
- Maximum
- consult physician
- Frequency
- single infusion over 2 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 420 IU/kg (anti-protective antigen IgG)
- Maximum
- consult physician
- Frequency
- single infusion over 2 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
11 groupspregnancy
first trimesteruse only if clearly needed
use during pregnancy only if benefits outweigh potential risks to fetus
regular fetal monitoring recommended
Use with caution and monitor for adverse effects.
pregnancy
second trimesteruse only if clearly needed
use during pregnancy only if benefits outweigh potential risks
regular fetal monitoring recommended
Use with caution and monitor for adverse effects.
pregnancy
third trimesteruse only if clearly needed
use during pregnancy only if benefits outweigh potential risks
regular fetal monitoring and uterine activity monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment needed
compatible with breastfeeding; immunoglobulin G crosses minimally into breast milk
no specific monitoring required
pediatric_age
neonatesweight-based dosing required
use in neonates only if benefits outweigh risks; limited safety data
monitor vital signs and for signs of hypersensitivity
Use with caution and monitor for adverse effects.
pediatric_age
childrenweight-based dosing
approved for use in pediatric patients; follow weight-based dosing guidelines
monitor for infusion reactions and hypersensitivity
geriatric
elderlyno specific adjustment needed
use standard dosing; consider comorbidities
monitor renal function and fluid status
renal_impairment
mildno adjustment needed
use standard dosing; monitor renal function
monitor serum creatinine and renal function
renal_impairment
severeuse with caution
use with caution due to fluid volume content; consider renal status
close monitoring of renal function and fluid balance
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderateno adjustment needed
use standard dosing
standard monitoring
hepatic_impairment
severeuse with caution
use with caution; limited data available
monitor liver function tests
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
FDA approval for Anthrax Immune Globulin Intravenous (Anthrasil)
Drug class
Classification as biological immune globulin product
Therapeutic indication
Primary therapeutic use in combination with antibacterial drugs
Mechanism of action
Provides antibodies against anthrax toxins
Treatment of inhalational anthrax in combination with appropriate antimicrobial therapy, particularly in cases of severe disease where systemic toxin effects are present or when there is evidence of disseminated infection.
Contains polyclonal antibodies that bind to and neutralize anthrax toxins (protective antigen, lethal factor, and edema factor), helping to reduce toxin-mediated tissue damage while antibiotics address the bacterial infection itself.
Administered intravenously under medical supervision. May cause infusion-related reactions including headache, flushing, or chills. Not a substitute for antimicrobial therapy. Derived from screened donor plasma. Efficacy is greatest when administered early in the disease course alongside antibiotics.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy